Literature DB >> 1943483

Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera.

S Akhtar1, R Kole, R L Juliano.   

Abstract

Antisense DNA oligodeoxynucleotides can selectively inhibit the expression of individual (undesirable) genes and thus, have potential in the treatment of cancer and viral diseases. A prerequisite to their use as therapeutic agents is information on the stability of oligodeoxynucleotides, and their structurally modified analogs, in the biological milieu. To this end, degradation of 5' end and internally [32P] labelled unmodified DNA oligodeoxynucleotide (D-oligo) and analogs containing phosphorothioate (S-oligo), methylphosphonate (MP-oligo), and novel alternating methylphosphonate and phosphodiester (Alt-MP-oligo) internucleoside linkages was studied in Hela cell nuclear extract, S100 cytoplasmic extract, normal human serum and calf serum at 37 degrees C. Both 5' end and internally labelled D-oligos showed complete degradation within 30 min incubation in human serum at 37 degrees C. In any given medium, the D-oligo was the least stable oligodeoxynucleotide to nuclease degradation whereas the Alt-MP, MP and S-oligos were generally of comparable stability and all relatively more stable than D-oligo. Interestingly, MP and Alt-MP-oligos also exhibited greater resistance to phosphatases in cellular extracts compared to D and S-oligos. Under the conditions of the experiments, increasing degradation for any given oligonucleotide was observed in the order: S100 cytoplasmic extract less than nuclear extract less than normal human serum less than calf serum. In a study involving alpha-MEM cell culture medium containing 10% heat inactivated fetal calf serum (heated to 56 degrees C for 1 hour), the D-oligo was found to be rapidly degraded (degradation evident within 10 mins) whereas degradation products for the S-oligo were observed within 1 hour. In contrast, the Alt-MP oligo remained stable throughout the 3 hour experiment. These results indicated that in cell culture medium containing heat inactivated serum Alt-MP oligo was more stable than D- and S-oligos.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1943483     DOI: 10.1016/0024-3205(91)90480-y

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  42 in total

1.  Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb.

Authors:  I J Moon; Y Lee; C S Kwak; J H Lee; K Choi; A D Schreiber; J G Park
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

Review 2.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

3.  Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry.

Authors:  Angelika Gabler; Stefan Krebs; Doris Seichter; Martin Förster
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

4.  The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts.

Authors:  B C Chu; L E Orgel
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

5.  Alternative for anti-TNF antibodies for arthritis treatment.

Authors:  Joseph Paquet; Christel Henrionnet; Astrid Pinzano; Jean-Baptiste Vincourt; Pierre Gillet; Patrick Netter; Isabelle Chary-Valckenaere; Damien Loeuille; Jacques Pourel; Laurent Grossin
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

Review 6.  Application of antisense DNA method for the study of molecular bases of brain function and behavior.

Authors:  S Ogawa; D W Pfaff
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

7.  A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum.

Authors:  J P Shaw; J A Fishback; K C Cundy; W A Lee
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

8.  Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors.

Authors:  M Rubenstein; Y Mirochnik; V Ray; P Guinan
Journal:  Med Oncol       Date:  1997 Sep-Dec       Impact factor: 3.064

9.  Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells.

Authors:  G F Beck; W J Irwin; P L Nicklin; S Akhtar
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

10.  Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.

Authors:  N M Dean; R McKay
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.